|
Market Cap (5-Jul) $17,064,960 (1,393rd) |
Close (30-Jun) $0.012 |
Volume (30-Jun) 5,851,219 |
Shortsold (10-Feb) 98,846 (0.00%) (597th) |
|
52w High $6.00 |
52w Low $0.80 |
P/E - |
EPS -1.79 |
OSL released this announcement to the ASX on 31 August 2022, 9:31. The announcement is not marked as price sensitive, and is 27 page(s) in length and 631.85kb in size.
You can view all announcements from OSL and see how they appear on a price chart on the announcements page.
At the date of this announcement, OSL was 0.681% short sold according to ASIC data. It was ranked the 246th most shorted stock on the ASX. It remains ranked 597th as of the latest reported data (10 February 2025).
| Other Recent Announcements from OSL | |
|---|---|
| Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer | 30 June 2023, 9:49 |
| Notification of cessation of securities - OSL | 29 June 2023, 17:51 |
| Ethics Committee Approves PANCOSIL Clinical Trial | 5 June 2023, 9:31 |
| Appendix 4G and Corporate Governance Statement | 31 August 2022, 9:31 |
| Appendix 4E Announcement | 31 August 2022, 8:38 |
| Appendix 4E and Annual Report | 31 August 2022, 8:37 |
| Investor Presentation | 3 August 2022, 13:57 |
You must be logged in to post a reply.
OncoSil Medical 